APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1 and PD-L1 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global PD-1 and PD-L1 Inhibitor Market Analysis and Forecast 2026-2032

30 December 2025198 pages

Choose your research edition.

Industry ResearchPD-1 and PD-L1 Inhibitor Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1 and PD-L1 Inhibitor Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal PD-1 and PD-L1 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1 and PD-L1 Inhibitor Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1 and PD-L1 Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global PD-1 and PD-L1 Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for PD-1 and PD-L1 Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of PD-1 and PD-L1 Inhibitor include Bristol Myers Squibb, Bristol-Myers Squibb, Regeneron Pharmaceuticals, AstraZeneca, Beigene, Hengrui Medicine, Pfizer, Junshi Biosciences and Akeso, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for PD-1 and PD-L1 Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of PD-1 and PD-L1 Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for PD-1 and PD-L1 Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PD-1 and PD-L1 Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global PD-1 and PD-L1 Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for PD-1 and PD-L1 Inhibitor sales, projected growth trends, production technology, application and end-user industry.

PD-1 and PD-L1 Inhibitor Segment by Company

Bristol Myers Squibb

Bristol-Myers Squibb

Regeneron Pharmaceuticals

AstraZeneca

Beigene

Hengrui Medicine

Pfizer

Junshi Biosciences

Akeso

Alphamab Oncology

Roche

Merck

Sanofi

Innovent Biologics

PD-1 and PD-L1 Inhibitor Segment by Type

Monoclonal Antibody

Bispecific Antibody

PD-1 and PD-L1 Inhibitor Segment by Application

Lung Cancer

Breast Cancer

Stomach Cancer

Rectal Cancer

Others

PD-1 and PD-L1 Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of PD-1 and PD-L1 Inhibitor in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of PD-1 and PD-L1 Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-1 and PD-L1 Inhibitor sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Monoclonal Antibody Major Manufacturers Table 3. Bispecific Antibody Major Manufacturers Table 4. Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Lung Cancer Major Manufacturers Table 6. Breast Cancer Major Manufacturers Table 7. Stomach Cancer Major Manufacturers Table 8. Rectal Cancer Major Manufacturers Table 9. Others Major Manufacturers Table 10. PD-1 and PD-L1 Inhibitor Industry Trends Table 11. PD-1 and PD-L1 Inhibitor Industry Drivers Table 12. PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges Table 13. PD-1 and PD-L1 Inhibitor Industry Restraints Table 14. Global PD-1 and PD-L1 Inhibitor Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2021-2026) & (US$ Million) Table 16. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2027-2032) & (US$ Million) Table 17. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2021-2026) Table 18. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2027-2032) Table 19. Global PD-1 and PD-L1 Inhibitor Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Tons) Table 20. Global PD-1 and PD-L1 Inhibitor Sales by Region (2021-2026) & (Tons) Table 21. Global PD-1 and PD-L1 Inhibitor Sales by Region (2027-2032) & (Tons) Table 22. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2021-2026) Table 23. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2027-2032) Table 24. Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Manufacturers (2021-2026) Table 26. Global PD-1 and PD-L1 Inhibitor Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2021-2026) Table 28. Global PD-1 and PD-L1 Inhibitor Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 29. Global PD-1 and PD-L1 Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global PD-1 and PD-L1 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global PD-1 and PD-L1 Inhibitor Manufacturers, Product Type & Application Table 32. Global PD-1 and PD-L1 Inhibitor Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global PD-1 and PD-L1 Inhibitor by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global PD-1 and PD-L1 Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 37. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 38. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2021-2026) Table 39. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2027-2032) Table 40. Global PD-1 and PD-L1 Inhibitor Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 41. Global PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 42. Global PD-1 and PD-L1 Inhibitor Sales by Type (2027-2032) & (Tons) Table 43. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2021-2026) Table 44. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2027-2032) Table 45. Global PD-1 and PD-L1 Inhibitor Price by Type (2021-2026) & (US$/Ton) Table 46. Global PD-1 and PD-L1 Inhibitor Price by Type (2027-2032) & (US$/Ton) Table 47. Global PD-1 and PD-L1 Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 49. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 50. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2021-2026) Table 51. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2027-2032) Table 52. Global PD-1 and PD-L1 Inhibitor Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 53. Global PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 54. Global PD-1 and PD-L1 Inhibitor Sales by Application (2027-2032) & (Tons) Table 55. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2021-2026) Table 56. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2027-2032) Table 57. Global PD-1 and PD-L1 Inhibitor Price by Application (2021-2026) & (US$/Ton) Table 58. Global PD-1 and PD-L1 Inhibitor Price by Application (2027-2032) & (US$/Ton) Table 59. Bristol Myers Squibb Company Information Table 60. Bristol Myers Squibb Business Overview Table 61. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 62. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio Table 63. Bristol Myers Squibb Recent Development Table 64. Bristol-Myers Squibb Company Information Table 65. Bristol-Myers Squibb Business Overview Table 66. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 67. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio Table 68. Bristol-Myers Squibb Recent Development Table 69. Regeneron Pharmaceuticals Company Information Table 70. Regeneron Pharmaceuticals Business Overview Table 71. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 72. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio Table 73. Regeneron Pharmaceuticals Recent Development Table 74. AstraZeneca Company Information Table 75. AstraZeneca Business Overview Table 76. AstraZeneca PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 77. AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio Table 78. AstraZeneca Recent Development Table 79. Beigene Company Information Table 80. Beigene Business Overview Table 81. Beigene PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 82. Beigene PD-1 and PD-L1 Inhibitor Product Portfolio Table 83. Beigene Recent Development Table 84. Hengrui Medicine Company Information Table 85. Hengrui Medicine Business Overview Table 86. Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 87. Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio Table 88. Hengrui Medicine Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 92. Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio Table 93. Pfizer Recent Development Table 94. Junshi Biosciences Company Information Table 95. Junshi Biosciences Business Overview Table 96. Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 97. Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio Table 98. Junshi Biosciences Recent Development Table 99. Akeso Company Information Table 100. Akeso Business Overview Table 101. Akeso PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 102. Akeso PD-1 and PD-L1 Inhibitor Product Portfolio Table 103. Akeso Recent Development Table 104. Alphamab Oncology Company Information Table 105. Alphamab Oncology Business Overview Table 106. Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 107. Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio Table 108. Alphamab Oncology Recent Development Table 109. Roche Company Information Table 110. Roche Business Overview Table 111. Roche PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 112. Roche PD-1 and PD-L1 Inhibitor Product Portfolio Table 113. Roche Recent Development Table 114. Merck Company Information Table 115. Merck Business Overview Table 116. Merck PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 117. Merck PD-1 and PD-L1 Inhibitor Product Portfolio Table 118. Merck Recent Development Table 119. Sanofi Company Information Table 120. Sanofi Business Overview Table 121. Sanofi PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 122. Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio Table 123. Sanofi Recent Development Table 124. Innovent Biologics Company Information Table 125. Innovent Biologics Business Overview Table 126. Innovent Biologics PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 127. Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio Table 128. Innovent Biologics Recent Development Table 129. North America PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 130. North America PD-1 and PD-L1 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 131. North America PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 132. North America PD-1 and PD-L1 Inhibitor Sales by Type (2027-2032) & (Tons) Table 133. North America PD-1 and PD-L1 Inhibitor Sales Price by Type (2021-2026) & (US$/Ton) Table 134. North America PD-1 and PD-L1 Inhibitor Sales Price by Type (2027-2032) & (US$/Ton) Table 135. North America PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 136. North America PD-1 and PD-L1 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 137. North America PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 138. North America PD-1 and PD-L1 Inhibitor Sales by Application (2027-2032) & (Tons) Table 139. North America PD-1 and PD-L1 Inhibitor Sales Price by Application (2021-2026) & (US$/Ton) Table 140. North America PD-1 and PD-L1 Inhibitor Sales Price by Application (2027-2032) & (US$/Ton) Table 141. North America PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 143. North America PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 144. North America PD-1 and PD-L1 Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 145. North America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 146. North America PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 147. North America PD-1 and PD-L1 Inhibitor Sales Price by Country (2021-2026) & (US$/Ton) Table 148. North America PD-1 and PD-L1 Inhibitor Sales Price by Country (2027-2032) & (US$/Ton) Table 149. United States PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 150. Canada PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 151. Europe PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 152. Europe PD-1 and PD-L1 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 153. Europe PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 154. Europe PD-1 and PD-L1 Inhibitor Sales by Type (2027-2032) & (Tons) Table 155. Europe PD-1 and PD-L1 Inhibitor Sales Price by Type (2021-2026) & (US$/Ton) Table 156. Europe PD-1 and PD-L1 Inhibitor Sales Price by Type (2027-2032) & (US$/Ton) Table 157. Europe PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 158. Europe PD-1 and PD-L1 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 159. Europe PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 160. Europe PD-1 and PD-L1 Inhibitor Sales by Application (2027-2032) & (Tons) Table 161. Europe PD-1 and PD-L1 Inhibitor Sales Price by Application (2021-2026) & (US$/Ton) Table 162. Europe PD-1 and PD-L1 Inhibitor Sales Price by Application (2027-2032) & (US$/Ton) Table 163. Europe PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 164. Europe PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 165. Europe PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 166. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 167. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 168. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 169. Europe PD-1 and PD-L1 Inhibitor Sales Price by Country (2021-2026) & (US$/Ton) Table 170. Europe PD-1 and PD-L1 Inhibitor Sales Price by Country (2027-2032) & (US$/Ton) Table 171. Germany PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 172. France PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 173. U.K. PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 174. Italy PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 175. Netherlands PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 176. China PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 177. China PD-1 and PD-L1 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 178. China PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 179. China PD-1 and PD-L1 Inhibitor Sales by Type (2027-2032) & (Tons) Table 180. China PD-1 and PD-L1 Inhibitor Sales Price by Type (2021-2026) & (US$/Ton) Table 181. China PD-1 and PD-L1 Inhibitor Sales Price by Type (2027-2032) & (US$/Ton) Table 182. China PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 183. China PD-1 and PD-L1 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 184. China PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 185. China PD-1 and PD-L1 Inhibitor Sales by Application (2027-2032) & (Tons) Table 186. China PD-1 and PD-L1 Inhibitor Sales Price by Application (2021-2026) & (US$/Ton) Table 187. China PD-1 and PD-L1 Inhibitor Sales Price by Application (2027-2032) & (US$/Ton) Table 188. Asia PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 189. Asia PD-1 and PD-L1 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 190. Asia PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 191. Asia PD-1 and PD-L1 Inhibitor Sales by Type (2027-2032) & (Tons) Table 192. Asia PD-1 and PD-L1 Inhibitor Sales Price by Type (2021-2026) & (US$/Ton) Table 193. Asia PD-1 and PD-L1 Inhibitor Sales Price by Type (2027-2032) & (US$/Ton) Table 194. Asia PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 195. Asia PD-1 and PD-L1 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 196. Asia PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 197. Asia PD-1 and PD-L1 Inhibitor Sales by Application (2027-2032) & (Tons) Table 198. Asia PD-1 and PD-L1 Inhibitor Sales Price by Application (2021-2026) & (US$/Ton) Table 199. Asia PD-1 and PD-L1 Inhibitor Sales Price by Application (2027-2032) & (US$/Ton) Table 200. Asia PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 201. Asia PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 202. Asia PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 203. Asia PD-1 and PD-L1 Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 204. Asia PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 205. Asia PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 206. Asia PD-1 and PD-L1 Inhibitor Sales Price by Country (2021-2026) & (US$/Ton) Table 207. Asia PD-1 and PD-L1 Inhibitor Sales Price by Country (2027-2032) & (US$/Ton) Table 208. Japan PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 209. South Korea PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 210. India PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 211. Australia PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 212. China Taiwan PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 213. Southeast Asia PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 214. SAMEA PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 215. SAMEA PD-1 and PD-L1 Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 216. SAMEA PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 217. SAMEA PD-1 and PD-L1 Inhibitor Sales by Type (2027-2032) & (Tons) Table 218. SAMEA PD-1 and PD-L1 Inhibitor Sales Price by Type (2021-2026) & (US$/Ton) Table 219. SAMEA PD-1 and PD-L1 Inhibitor Sales Price by Type (2027-2032) & (US$/Ton) Table 220. SAMEA PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 221. SAMEA PD-1 and PD-L1 Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 222. SAMEA PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 223. SAMEA PD-1 and PD-L1 Inhibitor Sales by Application (2027-2032) & (Tons) Table 224. SAMEA PD-1 and PD-L1 Inhibitor Sales Price by Application (2021-2026) & (US$/Ton) Table 225. SAMEA PD-1 and PD-L1 Inhibitor Sales Price by Application (2027-2032) & (US$/Ton) Table 226. SAMEA PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 227. SAMEA PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 228. SAMEA PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 229. SAMEA PD-1 and PD-L1 Inhibitor Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 230. SAMEA PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 231. SAMEA PD-1 and PD-L1 Inhibitor Sales by Country (2027-2032) & (Tons) Table 232. SAMEA PD-1 and PD-L1 Inhibitor Sales Price by Country (2021-2026) & (US$/Ton) Table 233. SAMEA PD-1 and PD-L1 Inhibitor Sales Price by Country (2027-2032) & (US$/Ton) Table 234. Brazil PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 235. Argentina PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 236. Chile PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 237. Colombia PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 238. Peru PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 239. Saudi Arabia PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 240. Israel PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 241. UAE PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 242. Turkey PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 243. Iran PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 244. Egypt PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Table 245. Key Raw Materials Table 246. Raw Materials Key Suppliers Table 247. PD-1 and PD-L1 Inhibitor Distributors List Table 248. PD-1 and PD-L1 Inhibitor Customers List Table 249. Research Programs/Design for This Report Table 250. Authors List of This Report Table 251. Secondary Sources Table 252. Primary Sources List of Figures Figure 1. PD-1 and PD-L1 Inhibitor Image Figure 2. Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1 and PD-L1 Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Monoclonal Antibody Image Figure 5. Bispecific Antibody Image Figure 6. Global PD-1 and PD-L1 Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global PD-1 and PD-L1 Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 8. Lung Cancer Image Figure 9. Breast Cancer Image Figure 10. Stomach Cancer Image Figure 11. Rectal Cancer Image Figure 12. Others Image Figure 13. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global PD-1 and PD-L1 Inhibitor Revenue (2021-2032) & (US$ Million) Figure 15. Global PD-1 and PD-L1 Inhibitor Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2021-2032) Figure 18. Global PD-1 and PD-L1 Inhibitor Sales (2021-2032) & (Tons) Figure 19. Global PD-1 and PD-L1 Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 20. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico PD-1 and PD-L1 Inhibitor Sales YoY (2021-2032) & (Tons) Figure 22. Europe PD-1 and PD-L1 Inhibitor Sales YoY (2021-2032) & (Tons) Figure 23. China PD-1 and PD-L1 Inhibitor Sales YoY (2021-2032) & (Tons) Figure 24. Asia (Excluding China) PD-1 and PD-L1 Inhibitor Sales YoY (2021-2032) & (Tons) Figure 25. South America, Middle East and Africa PD-1 and PD-L1 Inhibitor Sales YoY (2021-2032) & (Tons) Figure 26. Global PD-1 and PD-L1 Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global PD-1 and PD-L1 Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global PD-1 and PD-L1 Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2021-2032) Figure 32. Global PD-1 and PD-L1 Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 33. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2021-2032) Figure 35. Global PD-1 and PD-L1 Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2021-2032) Figure 38. Global PD-1 and PD-L1 Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 39. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2021-2032) Figure 41. North America PD-1 and PD-L1 Inhibitor Revenue Share by Type (2021-2032) Figure 42. North America PD-1 and PD-L1 Inhibitor Sales Share by Type (2021-2032) Figure 43. North America PD-1 and PD-L1 Inhibitor Revenue Share by Application (2021-2032) Figure 44. North America PD-1 and PD-L1 Inhibitor Sales Share by Application (2021-2032) Figure 45. North America PD-1 and PD-L1 Inhibitor Revenue Share by Country (2021-2032) Figure 46. North America PD-1 and PD-L1 Inhibitor Sales Share by Country (2021-2032) Figure 47. Europe PD-1 and PD-L1 Inhibitor Revenue Share by Type (2021-2032) Figure 48. Europe PD-1 and PD-L1 Inhibitor Sales Share by Type (2021-2032) Figure 49. Europe PD-1 and PD-L1 Inhibitor Revenue Share by Application (2021-2032) Figure 50. Europe PD-1 and PD-L1 Inhibitor Sales Share by Application (2021-2032) Figure 51. Europe PD-1 and PD-L1 Inhibitor Revenue Share by Country (2021-2032) Figure 52. Europe PD-1 and PD-L1 Inhibitor Sales Share by Country (2021-2032) Figure 53. China PD-1 and PD-L1 Inhibitor Revenue Share by Type (2021-2032) Figure 54. China PD-1 and PD-L1 Inhibitor Sales Share by Type (2021-2032) Figure 55. China PD-1 and PD-L1 Inhibitor Revenue Share by Application (2021-2032) Figure 56. China PD-1 and PD-L1 Inhibitor Sales Share by Application (2021-2032) Figure 57. Asia PD-1 and PD-L1 Inhibitor Revenue Share by Type (2021-2032) Figure 58. Asia PD-1 and PD-L1 Inhibitor Sales Share by Type (2021-2032) Figure 59. Asia PD-1 and PD-L1 Inhibitor Revenue Share by Application (2021-2032) Figure 60. Asia PD-1 and PD-L1 Inhibitor Sales Share by Application (2021-2032) Figure 61. Asia PD-1 and PD-L1 Inhibitor Revenue Share by Country (2021-2032) Figure 62. Asia PD-1 and PD-L1 Inhibitor Sales Share by Country (2021-2032) Figure 63. SAMEA PD-1 and PD-L1 Inhibitor Revenue Share by Type (2021-2032) Figure 64. SAMEA PD-1 and PD-L1 Inhibitor Sales Share by Type (2021-2032) Figure 65. SAMEA PD-1 and PD-L1 Inhibitor Revenue Share by Application (2021-2032) Figure 66. SAMEA PD-1 and PD-L1 Inhibitor Sales Share by Application (2021-2032) Figure 67. SAMEA PD-1 and PD-L1 Inhibitor Revenue Share by Country (2021-2032) Figure 68. SAMEA PD-1 and PD-L1 Inhibitor Sales Share by Country (2021-2032) Figure 69. PD-1 and PD-L1 Inhibitor Value Chain Figure 70. Manufacturing Cost Structure Figure 71. PD-1 and PD-L1 Inhibitor Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • Bispecific Antibody
Applications
  • Lung Cancer
  • Breast Cancer
  • Stomach Cancer
  • Rectal Cancer
  • Others
Companies covered
  • Bristol Myers Squibb
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals
  • AstraZeneca
  • Beigene
  • Hengrui Medicine
  • Pfizer
  • Junshi Biosciences
  • Akeso
  • Alphamab Oncology
  • Roche
  • Merck
  • Sanofi
  • Innovent Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 PD-1 and PD-L1 Inhibitor Market by Type
  3. 1.2.1 Global PD-1 and PD-L1 Inhibitor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Monoclonal Antibody
  5. 1.2.3 Bispecific Antibody
  6. 1.3 PD-1 and PD-L1 Inhibitor Market by Application
  7. 1.3.1 Global PD-1 and PD-L1 Inhibitor Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Lung Cancer
  9. 1.3.3 Breast Cancer
  10. 1.3.4 Stomach Cancer
  11. 1.3.5 Rectal Cancer
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 PD-1 and PD-L1 Inhibitor Market Dynamics
  1. 2.1 PD-1 and PD-L1 Inhibitor Industry Trends
  2. 2.2 PD-1 and PD-L1 Inhibitor Industry Drivers
  3. 2.3 PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges
  4. 2.4 PD-1 and PD-L1 Inhibitor Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global PD-1 and PD-L1 Inhibitor Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Region
  3. 3.2.1 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global PD-1 and PD-L1 Inhibitor Revenue by Region (2021-2026)
  5. 3.2.3 Global PD-1 and PD-L1 Inhibitor Revenue by Region (2027-2032)
  6. 3.2.4 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2021-2032)
  7. 3.3 Global PD-1 and PD-L1 Inhibitor Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global PD-1 and PD-L1 Inhibitor Sales by Region
  9. 3.4.1 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global PD-1 and PD-L1 Inhibitor Sales by Region (2021-2026)
  11. 3.4.3 Global PD-1 and PD-L1 Inhibitor Sales by Region (2027-2032)
  12. 3.4.4 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers
  2. 4.1.1 Global PD-1 and PD-L1 Inhibitor Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global PD-1 and PD-L1 Inhibitor Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global PD-1 and PD-L1 Inhibitor Sales by Manufacturers
  6. 4.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global PD-1 and PD-L1 Inhibitor Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global PD-1 and PD-L1 Inhibitor Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global PD-1 and PD-L1 Inhibitor Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global PD-1 and PD-L1 Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global PD-1 and PD-L1 Inhibitor Manufacturers, Product Type & Application
  13. 4.7 Global PD-1 and PD-L1 Inhibitor Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global PD-1 and PD-L1 Inhibitor Market CR5 and HHI
  16. 4.8.2 2025 PD-1 and PD-L1 Inhibitor Tier 1, Tier 2, and Tier 3
5 PD-1 and PD-L1 Inhibitor Market by Type
  1. 5.1 Global PD-1 and PD-L1 Inhibitor Revenue by Type
  2. 5.1.1 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2021-2032)
  5. 5.2 Global PD-1 and PD-L1 Inhibitor Sales by Type
  6. 5.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PD-1 and PD-L1 Inhibitor Sales by Type (2021-2032) & (Tons)
  8. 5.2.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2021-2032)
  9. 5.3 Global PD-1 and PD-L1 Inhibitor Price by Type
6 PD-1 and PD-L1 Inhibitor Market by Application
  1. 6.1 Global PD-1 and PD-L1 Inhibitor Revenue by Application
  2. 6.1.1 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2021-2032)
  5. 6.2 Global PD-1 and PD-L1 Inhibitor Sales by Application
  6. 6.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global PD-1 and PD-L1 Inhibitor Sales by Application (2021-2032) & (Tons)
  8. 6.2.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2021-2032)
  9. 6.3 Global PD-1 and PD-L1 Inhibitor Price by Application
7 Company Profiles
  1. 7.1 Bristol Myers Squibb
  2. 7.1.1 Bristol Myers Squibb Company Information
  3. 7.1.2 Bristol Myers Squibb Business Overview
  4. 7.1.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
  6. 7.1.5 Bristol Myers Squibb Recent Developments
  7. 7.2 Bristol-Myers Squibb
  8. 7.2.1 Bristol-Myers Squibb Company Information
  9. 7.2.2 Bristol-Myers Squibb Business Overview
  10. 7.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
  12. 7.2.5 Bristol-Myers Squibb Recent Developments
  13. 7.3 Regeneron Pharmaceuticals
  14. 7.3.1 Regeneron Pharmaceuticals Company Information
  15. 7.3.2 Regeneron Pharmaceuticals Business Overview
  16. 7.3.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio
  18. 7.3.5 Regeneron Pharmaceuticals Recent Developments
  19. 7.4 AstraZeneca
  20. 7.4.1 AstraZeneca Company Information
  21. 7.4.2 AstraZeneca Business Overview
  22. 7.4.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio
  24. 7.4.5 AstraZeneca Recent Developments
  25. 7.5 Beigene
  26. 7.5.1 Beigene Company Information
  27. 7.5.2 Beigene Business Overview
  28. 7.5.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Beigene PD-1 and PD-L1 Inhibitor Product Portfolio
  30. 7.5.5 Beigene Recent Developments
  31. 7.6 Hengrui Medicine
  32. 7.6.1 Hengrui Medicine Company Information
  33. 7.6.2 Hengrui Medicine Business Overview
  34. 7.6.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio
  36. 7.6.5 Hengrui Medicine Recent Developments
  37. 7.7 Pfizer
  38. 7.7.1 Pfizer Company Information
  39. 7.7.2 Pfizer Business Overview
  40. 7.7.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio
  42. 7.7.5 Pfizer Recent Developments
  43. 7.8 Junshi Biosciences
  44. 7.8.1 Junshi Biosciences Company Information
  45. 7.8.2 Junshi Biosciences Business Overview
  46. 7.8.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio
  48. 7.8.5 Junshi Biosciences Recent Developments
  49. 7.9 Akeso
  50. 7.9.1 Akeso Company Information
  51. 7.9.2 Akeso Business Overview
  52. 7.9.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Akeso PD-1 and PD-L1 Inhibitor Product Portfolio
  54. 7.9.5 Akeso Recent Developments
  55. 7.10 Alphamab Oncology
  56. 7.10.1 Alphamab Oncology Company Information
  57. 7.10.2 Alphamab Oncology Business Overview
  58. 7.10.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio
  60. 7.10.5 Alphamab Oncology Recent Developments
  61. 7.11 Roche
  62. 7.11.1 Roche Company Information
  63. 7.11.2 Roche Business Overview
  64. 7.11.3 Roche PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Roche PD-1 and PD-L1 Inhibitor Product Portfolio
  66. 7.11.5 Roche Recent Developments
  67. 7.12 Merck
  68. 7.12.1 Merck Company Information
  69. 7.12.2 Merck Business Overview
  70. 7.12.3 Merck PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Merck PD-1 and PD-L1 Inhibitor Product Portfolio
  72. 7.12.5 Merck Recent Developments
  73. 7.13 Sanofi
  74. 7.13.1 Sanofi Company Information
  75. 7.13.2 Sanofi Business Overview
  76. 7.13.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio
  78. 7.13.5 Sanofi Recent Developments
  79. 7.14 Innovent Biologics
  80. 7.14.1 Innovent Biologics Company Information
  81. 7.14.2 Innovent Biologics Business Overview
  82. 7.14.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio
  84. 7.14.5 Innovent Biologics Recent Developments
8 North America
  1. 8.1 North America PD-1 and PD-L1 Inhibitor Market Size by Type
  2. 8.1.1 North America PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2032)
  3. 8.1.2 North America PD-1 and PD-L1 Inhibitor Sales by Type (2021-2032)
  4. 8.1.3 North America PD-1 and PD-L1 Inhibitor Price by Type (2021-2032)
  5. 8.2 North America PD-1 and PD-L1 Inhibitor Market Size by Application
  6. 8.2.1 North America PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2032)
  7. 8.2.2 North America PD-1 and PD-L1 Inhibitor Sales by Application (2021-2032)
  8. 8.2.3 North America PD-1 and PD-L1 Inhibitor Price by Application (2021-2032)
  9. 8.3 North America PD-1 and PD-L1 Inhibitor Market Size by Country
  10. 8.3.1 North America PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America PD-1 and PD-L1 Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America PD-1 and PD-L1 Inhibitor Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe PD-1 and PD-L1 Inhibitor Market Size by Type
  2. 9.1.1 Europe PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2032)
  3. 9.1.2 Europe PD-1 and PD-L1 Inhibitor Sales by Type (2021-2032)
  4. 9.1.3 Europe PD-1 and PD-L1 Inhibitor Price by Type (2021-2032)
  5. 9.2 Europe PD-1 and PD-L1 Inhibitor Market Size by Application
  6. 9.2.1 Europe PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2032)
  7. 9.2.2 Europe PD-1 and PD-L1 Inhibitor Sales by Application (2021-2032)
  8. 9.2.3 Europe PD-1 and PD-L1 Inhibitor Price by Application (2021-2032)
  9. 9.3 Europe PD-1 and PD-L1 Inhibitor Market Size by Country
  10. 9.3.1 Europe PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe PD-1 and PD-L1 Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe PD-1 and PD-L1 Inhibitor Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China PD-1 and PD-L1 Inhibitor Market Size by Type
  2. 10.1.1 China PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2032)
  3. 10.1.2 China PD-1 and PD-L1 Inhibitor Sales by Type (2021-2032)
  4. 10.1.3 China PD-1 and PD-L1 Inhibitor Price by Type (2021-2032)
  5. 10.2 China PD-1 and PD-L1 Inhibitor Market Size by Application
  6. 10.2.1 China PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2032)
  7. 10.2.2 China PD-1 and PD-L1 Inhibitor Sales by Application (2021-2032)
  8. 10.2.3 China PD-1 and PD-L1 Inhibitor Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia PD-1 and PD-L1 Inhibitor Market Size by Type
  2. 11.1.1 Asia PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2032)
  3. 11.1.2 Asia PD-1 and PD-L1 Inhibitor Sales by Type (2021-2032)
  4. 11.1.3 Asia PD-1 and PD-L1 Inhibitor Price by Type (2021-2032)
  5. 11.2 Asia PD-1 and PD-L1 Inhibitor Market Size by Application
  6. 11.2.1 Asia PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2032)
  7. 11.2.2 Asia PD-1 and PD-L1 Inhibitor Sales by Application (2021-2032)
  8. 11.2.3 Asia PD-1 and PD-L1 Inhibitor Price by Application (2021-2032)
  9. 11.3 Asia PD-1 and PD-L1 Inhibitor Market Size by Country
  10. 11.3.1 Asia PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia PD-1 and PD-L1 Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia PD-1 and PD-L1 Inhibitor Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA PD-1 and PD-L1 Inhibitor Market Size by Type
  2. 12.1.1 SAMEA PD-1 and PD-L1 Inhibitor Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA PD-1 and PD-L1 Inhibitor Sales by Type (2021-2032)
  4. 12.1.3 SAMEA PD-1 and PD-L1 Inhibitor Price by Type (2021-2032)
  5. 12.2 SAMEA PD-1 and PD-L1 Inhibitor Market Size by Application
  6. 12.2.1 SAMEA PD-1 and PD-L1 Inhibitor Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA PD-1 and PD-L1 Inhibitor Sales by Application (2021-2032)
  8. 12.2.3 SAMEA PD-1 and PD-L1 Inhibitor Price by Application (2021-2032)
  9. 12.3 SAMEA PD-1 and PD-L1 Inhibitor Market Size by Country
  10. 12.3.1 SAMEA PD-1 and PD-L1 Inhibitor Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA PD-1 and PD-L1 Inhibitor Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA PD-1 and PD-L1 Inhibitor Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 PD-1 and PD-L1 Inhibitor Value Chain Analysis
  2. 13.1.1 PD-1 and PD-L1 Inhibitor Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 PD-1 and PD-L1 Inhibitor Production Mode & Process
  6. 13.2 PD-1 and PD-L1 Inhibitor Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 PD-1 and PD-L1 Inhibitor Distributors
  9. 13.2.3 PD-1 and PD-L1 Inhibitor Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst